The Seoul-based medical aesthetics company is adding a botulinum toxin type A brand to its international portfolio.
CELSET has introduced SOLTOX, a South Korean botulinum toxin type A brand for the medical aesthetics sector. The Seoul-based company announced the international launch in late October and says it plans to develop the brand through established medical channels and relationships with healthcare professionals.
The launch materials focus on the product’s identity, packaging and information for healthcare professionals. CELSET describes a consistent brand presentation as part of its approach across markets.
The announcement leaves country-by-country availability open. CELSET says availability and use depend on local regulatory requirements. It did not name launch markets, give a rollout timetable or announce approvals in specific countries.